Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.54 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.54 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.52 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4376615 | 1.00 | ALDH1A1 (0.59) | ALDH1A1LMNACES2CES1PARP10 | |
| Terephthalamide SCHEMBL17907469 | 0.97 | ALDH1A1 (0.62) | ALDH1A1LMNACES2CES1PARP10 | |
| SCHEMBL76475 | 0.97 | ALDH1A1 (0.62) | ALDH1A1LMNACES2CES1PARP10 | |
| SCHEMBL30775329 | 0.95 | ALDH1A1 (0.59) | ALDH1A1LMNACES2CES1PARP10 | |
| SCHEMBL10416433 | 0.95 | ALDH1A1 (0.59) | ALDH1A1LMNACES2CES1PARP10 | |
| Hydrazine SCHEMBL28484381 | 0.95 | ALDH1A1 (0.59) | ALDH1A1LMNACES2CES1PARP10 | |
| Benzene SCHEMBL28164652 | 0.92 | PARP1 (0.64) | ALDH1A1LMNACES2CES1PARP10 | |
| Hydrochloric Acid SCHEMBL4879563 | 0.92 | ALDH1A1 (0.56) | ALDH1A1LMNACES2CES1PARP10 | |
| SCHEMBL5981249 | 0.90 | CA1 (0.55) | ALDH1A1LMNACES2CES1PARP10 | |
| SCHEMBL20705487 | 0.90 | CA1 (0.55) | ALDH1A1LMNACES2CES1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| CN-112521636-B | Asphaltene dissolution and dispersion process | 英菲诺姆国际有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-112521977-B | Anti-scaling method for oil refinery | 英菲诺姆国际有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117362192-A | PET radioactive tracer for imaging glycine transporter Glyt2 | 浙江颐核医疗科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220274991-A1 | SMALL MOLECULE INHIBITORS OF KU70/80 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-09-01 | — | — | US | disclosed |
| EP-2468717-B1 | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2468717-A1 | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | Bristol-Myers Squibb Company (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-6380187-B2 | FUNGICIDES | YU DINGWEI TIM (US) | 2002-04-30 | — | — | US | disclosed |
| US-20020002193-A1 | Thiadiazole antifungal agents | YU DINGWEI TIM (US) | 2002-01-03 | — | — | US | disclosed |
| US-6281217-B2 | ANTIFUNGAL ACTIVITY AGAINST A VARIETY OF FUNGI INCLUDING STRAINS WHICH HAVE PROVEN TO BE RESISTANT TO TREATMENT WITH KNOWN ANTIFUNGAL AGENTS SUCH AS FLUCONAZOLE. | YU DINGWEI TIM (US) | 2001-08-28 | — | — | US | disclosed |
| US-6277873-B1 | CONTROLLING DRUG RESISTANT FUNGI | YU DINGWEI TIM (US) | 2001-08-21 | — | — | US | disclosed |
| US-20010000512-A1 | Novel class of piperazino substituted thiazoles | YU DINGWEI TIM (US) | 2001-04-26 | — | — | US | disclosed |
| US-20010000177-A1 | Novel class of thiomorpholino substituted thiazoles | YU DINGWEI TIM (US) | 2001-04-05 | — | — | US | disclosed |
| US-20010000178-A1 | PYRIDYL SUBSTITUTED THIAZOLES | YU DINGWEI TIM (US) | 2001-04-05 | — | — | US | disclosed |
| US-6156776-A | Diaryl substituted thiazoles useful in the treatment of fungal infections | YU DINGWEI TIM (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000177-A1 | Novel class of thiomorpholino substituted thiazoles | THUMPD1, ERG28, THOC2 | PARP1 4680/4885CA2 4010/4885GAA 2975/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | PARP1 452/4885CA2 4739/4885GAA 4453/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | PARP1 4152/4885CA2 1228/4885GAA 261/4885 |
| US-20020002193-A1 | Thiadiazole antifungal agents | ERG28, NAT1, AADAC | PARP1 3564/4885CA2 4548/4885GAA 1147/4885 |
| US-20010000512-A1 | Novel class of piperazino substituted thiazoles | ERG28, DPM1, NAT1 | PARP1 4001/4885CA2 4258/4885GAA 1481/4885 |
| US-20010000178-A1 | PYRIDYL SUBSTITUTED THIAZOLES | PDXK, OXA1L, ERG28 | PARP1 3802/4885CA2 4421/4885GAA 1705/4885 |
| US-20220274991-A1 | SMALL MOLECULE INHIBITORS OF KU70/80 AND USES THEREOF | XRCC6, XRCC5, RAD50 | PARP1 33/4885CA2 4879/4885GAA 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.